Agenus reports Q3 EPS (16c), consensus (19c)

Reports Q3 revenue $24.3M, consensus $24.33M. Reports end of Q3 cash, cash equivalent, and short-term investment balance of $106.3M. Along with four planned transactions, believes the company is sufficiently funded through the end of 2024. “The botensilimab franchise, after treating more than 750 patients, has demonstrated consistent tumor responses across a diverse range of nine tumor types, showcasing its potential for significant impact in oncology,” said CEO Garo Armen. “The emerging data indicating the efficacy of botensilimab in earlier stages of cancer marks a notable shift towards less invasive treatment options. Agenus is forging ahead with a focus on our regulatory filing in CRC, advancing our robust clinical pipeline, and committing to deliver substantial outcomes for patients and create value for our shareholders.”